This study was designed to evaluate the actual efficacy of a single agent systemic therapy in the IMDC favorable risk group patients with mRCC. Methods: A total of 240 patients with mRCC who received systemic therapy were retrospectively reviewed (Institutional review board approval No 2013-0425)....
The risk group and corresponding estimated median survival in the TKI era will be displayed at the bottom of the calculator. - Use baseline factors at the start date of the current line of systemic therapy, except for the “time from diagnosis to systemic therapy” criterion, which is always...
In regression analysis, the survival results in the good IMDC risk group were superior to those in the intermediate/poor IMDC group (hazard ratio for death 0.27, 95% CI: 0.08-0.92; p=0.037; hazard ratio for progression 0.33, 95% CI: 0.11-0.96; p=0.042). Conclusions The combination of ...
(P <0.05,butthedifferenceinthehigh-riskgroup waslimitedto1yearsurvival), whiletherewasnosignificantdifferenceregardingoligometastaticstatusintheIMDClow-riskgroup(P>0.05).Conclusion: TheIMDC-Oligmodelcanwellre-stratifypatientsintheintermediateandhighIMDCriskgroupsbasedontheoverallriskof death,andcanbeusedasan...
The IMDC group showed a significant effect on OS (p=0.002). The intermediate- and poor-risk groups had 12- and 4-month OS, respectively. The TTI risk factor excluded patient numbers in the favorable, intermediate, and poor risk groups were 47, 129, and 29, respectively, in the revised ...
Background Patients in the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate-risk group have heterogeneous prognoses and thus may benefit from improved risk...doi:10.1007/s11523-019-00634-8Takagi, ToshioFukuda, Hironori...
The hazard ratios (HRs) of the favorable risk group for both progression-free survival (PFS) and overall survival (OS) comparing the experimental arms to sunitinib were extracted. Responses were measured at 24 (durable response [DR]) and 36 months (extreme durable response [EDR]) and long-...
DISEASE risk factorsPROGNOSISNIVOLUMABOVERALL survivalIMDC is the most important prognostic score for 1 line mRCC; it might be useful in subsequent lines. 492 pts were analyzed for IMDC changes from baseline to 鈮 2 line nivolumab start. Longer mPFS and mOS were reached by...
Results: The results showed that the adjusted PNI-IMDC risk score, classic IMDC, and PNI had similar prognostic values. Adjusted PNI-IMDC risk score might be used for a more homogeneous differentiation of the classic intermediate group. On the other hand, multivariate analysis revealed that the ...
RESULTS: According to IMDC prognostic model, 19.4% had favourable risk (FR), 57.2% intermediate risk (IR), and 23.4% poor risk (PR). No unexpected toxicities were recorded. Response rate was 30.3% (FR: 44%, IR: 30% PR: 17.3%). Median progression-free survival (whole population) was ...